Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 28Rituximab 23fludarabine 14fludarabine phosphate 12Specimen Handling 11obinutuzumab 10ibrutinib 10Magnetic Resonance Spectroscopy 10Prednisone 8Doxorubicin 8tocilizumab 7polatuzumab vedotin 7X-Rays 7Whole-Body Irradiation 7Phantoms, Imaging 7Mycophenolic Acid 7Etoposide 7Biopsy 7venetoclax 6glofitamab 6Melphalan 6Lenalidomide 6Bendamustine Hydrochloride 6pirtobrutinib 5acalabrutinib 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × belinostat × 90 days × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡